Our data provides a link between the loss of MAP4K5 and EMT in pancreatic cancer and may suggest that MAP4K5 signaling represents a potential therapeutic target for pancreatic cancer. This evidence concerns the gene MAP4K5 and familial pancreatic carcinoma.